Inc. (NASDAQ:SPLK), provider of the leading platform for real-time
Operational Intelligence, today announced that mail.de
GmbH , a German provider of email services, is optimizing its email
service and gaining real-time business insight by indexing, correlating
and visualizing its machine data with Splunk® Enterprise.
Louisiana-Pacific Corporation (LP) (NYSE: LPX) reported today results
for the third quarter of 2014, which included the following:
“LP’s financial results continue to be negatively affected by poor OSB
pricing,” said Curt Stevens, CEO.
Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage
biopharmaceutical company focused on developing novel therapies for
prostate cancer and other hormonally driven diseases, today announced
that updated, interim results from the company’s ongoing Phase 2
clinical trial, ARMOR2, of its lead drug candidate, galeterone, in
patients with castration resistant prostate cancer (CRPC) will be
presented at the 26 th EORTC-NCI-AACR Symposium on Molecular
Targets in Cancer Therapeutics being held November 18-21 in Barcelona,
Nu Skin Enterprises' stock (NUS) tumbled 12% in premarket trade Wednesday, after the maker of skin care products provided a profit and sales outlook for the current quarter that was well below analyst projections.
Targacept, Inc. (NASDAQ: TRGT ),
a clinical-stage biopharmaceutical company advancing NNR Therapeutics™,
today reported its financial results for the third quarter and nine
months ended September 30, 2014.
Vishay Precision Group, Inc. (NYSE: VPG), a leading producer of
precision sensors and systems, based on its resistive foil technology,
today announced financial results for its third quarter ended September
Sciences Corporation (NYSE: ORB), one of the world’s leading space
technology companies, today announced comprehensive plans to fulfill its
contract commitments under NASA’s Commercial Resupply Services (CRS)
program as well as to accelerate an upgrade of the Antares
medium-class launcher’s main propulsion system.
- Third quarter contract revenue of $57.5 million, up 8% from 2013 - Lower Discovery and API revenue is offset by addition of OsoBio - OsoBio business interruption contributes to third quarter adjusted loss per share of $(0.02)
- Full year 2014 contract revenue expected to be between $253 and $261 million, an increase of 22% at the midpoint - Full year adjusted diluted EPS range between $0.67 and $0.73, compared to $0.70 in 2013 - Company provides initial 2015 outlook - Company creates new Drug Product reporting segment to reflect addition of OsoBio ALBANY, N.Y. , Nov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.